Tango Therapeutics (TNGX) Gains from Sales and Divestitures (2020 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Gains from Sales and Divestitures of $509756.0 in Q1 2026, up 6.18% quarter-over-quarter from $480077.0 in Q4 2025, and up 35.04% on a YoY basis from $377485.0 in Q1 2025.
Tango Therapeutics (TNGX) Gains from Sales and Divestitures (2020 - 2026) Analysis & Trends
Tango Therapeutics' Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $509756.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures rose 35.04% year-over-year to $509756.0; the TTM figure through Mar 2026 stood at $509756.0 (up 35.04% YoY), while the FY2025 annual figure was $480077.0, up 84.03% from the prior year.
- Gains from Sales and Divestitures was $509756.0 for Q1 2026 at Tango Therapeutics, up from $480077.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $509756.0 in Q1 2026 to a low of $37500.0 in Q2 2023.
- Historically, Gains from Sales and Divestitures has averaged $276007.6 across 4 years, with a median of $256990.5 in 2024.
- The sharpest annual moves came in 2024 and 2026: Gains from Sales and Divestitures soared 595.64% in 2024, then jumped 35.04% in 2026.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $37500.0 in 2023, then jumped by 595.64% to $260865.0 in 2024, then jumped by 84.03% to $480077.0 in 2025, then climbed by 6.18% to $509756.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $509756.0 (Q1 2026), $480077.0 (Q4 2025), and $454414.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 509,756.00 |
| Mar 31, 2026 | 509,756.00 |
| Dec 31, 2025 | 480,077.00 |
| Dec 31, 2025 | 480,077.00 |
| Sep 30, 2025 | 454,414.00 |
| Sep 30, 2025 | 454,414.00 |
| Jun 30, 2025 | 433,483.00 |
| Jun 30, 2025 | 433,483.00 |
| Mar 31, 2025 | 377,485.00 |
| Mar 31, 2025 | 377,485.00 |
| Dec 31, 2024 | 260,865.00 |
| Dec 31, 2024 | 260,865.00 |
| Sep 30, 2024 | 253,116.00 |
| Sep 30, 2024 | 253,116.00 |
| Jun 30, 2024 | 232,470.00 |
| Jun 30, 2024 | 232,470.00 |
| Mar 31, 2024 | 197,925.00 |
| Mar 31, 2024 | 197,925.00 |
| Dec 31, 2023 | 37,500.00 |
| Dec 31, 2023 | 37,500.00 |